Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. プロテアゼ活性化受容体4の喪失は,炎症の解消を阻害し,心筋梗塞後に心臓の破裂を誘発する.
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. プロテアゼ活性化受容体4の喪失は,炎症の解消を阻害し,心筋梗塞後に心臓の破裂を誘発する.

関連する実験動画

An Intact Pericardium Ischemic Rodent Model
07:15

An Intact Pericardium Ischemic Rodent Model

Published on: September 2, 2021

2.8K

プロテアゼ活性化受容体4の喪失は,炎症の解消を阻害し,心筋梗塞後に心臓の破裂を誘発する.

Mikhail A Kolpakov1, Xinji Guo1, Khadija Rafiq2

  • 1Cardiovascular Research Center and Department of Physiology, Temple University School of Medicine, Philadelphia, PA (M.A.K., X.G., L.V., B.H., R.S., T.W., X.F., D.G.T., J.C.K., S.P.K., S.R.H., A.S.).

Circulation
|June 4, 2020

PubMed で要約を見る

まとめ
この要約は機械生成です。

プロテアゼ活性化受容体4 (Par4) は心臓発作の回復に二重の役割を果たします. Par4の抑制は急性期に役立つかもしれないが,長期的な治癒を悪化させ,心臓破裂のリスクを高める.

科学分野:

  • 心血管生物学
  • 免疫学
  • 分子医学

背景:

  • 心筋梗塞 (MI) の後の死亡の重要な原因は心臓の破裂です.
  • リパルフュージョン治療の進歩にもかかわらず,心臓破裂による死亡率は高いままです.
  • 心臓の破裂を加速させるための血栓解消治療の役割は議論されている.

研究 の 目的:

  • 心筋梗塞 (MI) の文脈におけるプロテアゼ活性化受容体4 (Par4) の発現と機能を調査する.
  • 心臓発作後の心臓の再構成,機能,治癒に対する Par4 欠失の影響を決定する.

主な方法:

  • 心臓発作後のマウスのPar4 mRNAとタンパク質の分析
  • 野生型およびPar4欠乏性マウスの心筋再構成および機能の評価
  • ニュートロフィルのアポトーシスと炎症反応に関するin vitroおよびin vivo研究.

主要な成果:

  • マウスの心臓のパー4発現は,MI後および高縮性/炎症性刺激に対する反応として増加した.
  • Par4欠乏したマウスはミオサイトアポトーシスが減少し,心臓発作のサイズが小さくなり,急性機能回復が改善された.
  • 対照的に,Par4欠乏症のマウスは,遅延した中性粒子のアポトーシスと炎症解消の障害に関連して,長期的な心機能障害,心筋破裂の増加,およびより高い死亡率を示した.
キーワード:
心臓の破裂炎症心筋梗塞中性粒子プロテアゼ活性化受容体 4

さらに関連する動画

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

736
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.2K

関連する実験動画

An Intact Pericardium Ischemic Rodent Model
07:15

An Intact Pericardium Ischemic Rodent Model

Published on: September 2, 2021

2.8K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

736
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.2K

関連する概念動画

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

324
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
324
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

268
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
268
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

800
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
800
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

277
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
277
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

341
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
341
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

結論:

  • Par4は中性粒子のアポトーシスと炎症の早期解消に不可欠であり,MI後の効果的な心筋治癒に不可欠です.
  • Par4阻害は急性性不血症では有益ですが,長期的な回復には有害です.
  • Par4をターゲットにするには,心臓の修復に悪影響を及ぼすのを避けるために,治療のタイミングと期間を慎重に考慮する必要があります.